Stealth BioTherapeutics (NASDAQ:MITO) Given a $21.00 Price Target at HC Wainwright
Stealth BioTherapeutics (NASDAQ:MITO) has been given a $21.00 price objective by HC Wainwright in a research report issued on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 261.45% from the company’s previous close.
Several other brokerages also recently commented on MITO. Cantor Fitzgerald started coverage on shares of Stealth BioTherapeutics in a report on Friday, September 27th. They issued an “overweight” rating and a $18.00 target price on the stock. Zacks Investment Research downgraded shares of Stealth BioTherapeutics from a “buy” rating to a “sell” rating in a report on Wednesday. Nomura set a $28.00 price objective on shares of Stealth BioTherapeutics and gave the stock a “buy” rating in a report on Friday. Finally, Jefferies Financial Group set a $9.00 price objective on shares of Stealth BioTherapeutics and gave the stock a “hold” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Stealth BioTherapeutics currently has a consensus rating of “Buy” and an average target price of $21.86.
MITO traded down $0.57 during trading on Friday, hitting $5.81. The stock had a trading volume of 30,116 shares, compared to its average volume of 104,251. The firm has a market cap of $223.49 million and a PE ratio of -4.12. Stealth BioTherapeutics has a 12 month low of $4.97 and a 12 month high of $20.99. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 0.54. The company has a 50 day simple moving average of $7.05 and a 200-day simple moving average of $11.31.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Further Reading: Dividend Yield
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.